FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 150 filers reported holding FATE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $773,000 | -58.3% | 49,796 | -45.5% | 0.38% | -52.3% |
| Q2 2019 | $1,854,000 | +15.5% | 91,332 | 0.0% | 0.79% | +11.0% |
| Q1 2019 | $1,605,000 | +21.3% | 91,332 | -11.4% | 0.71% | -1.9% |
| Q4 2018 | $1,323,000 | -21.2% | 103,125 | 0.0% | 0.72% | +6.3% |
| Q3 2018 | $1,680,000 | +90.3% | 103,125 | +32.4% | 0.68% | +58.0% |
| Q2 2018 | $883,000 | +16.2% | 77,889 | 0.0% | 0.43% | +9.4% |
| Q1 2018 | $760,000 | – | 77,889 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |